E2F1 and gastric cancer: Furthermore, bioinformatics predictions and in vitro validation demonstrated that miR-532 can directly target E2F1 and effectively attenuate the promoting effect of E2F1 on the progression of GC in vitro and in vivo, while E2F1 can, in turn, be recruited to miR-532 promoter to inhibit the expression of miR-532.